Antibiotics and Antimycotics Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031

Antibiotics and Antimycotics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Penicillins, Cephalosporins, Carbapenems, Macrolides, Aminoglycosides, Quinolones, Sulfonamides, Tetracyclines, Azoles, and Others), Indication (Skin Infections, Respiratory Infections, Urinary Tract Infections, Septicemia, Ear Infections, Gastrointestinal Infections, and Others), Route of Administration (Oral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

  • Report Code : TIPRE00021878
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 203
Buy Now

The antibiotics and antimycotics market size is projected to reach US$ 91,546.07 million by 2031 from US$ 61,207.98 million in 2023. The market is expected to register a CAGR of 5.2% during 2023–2031. Technological advancements in product development and treatment delivery approaches are likely to bring new trends in the antibiotics and antimycotics market in the coming years.

Antibiotics and Antimycotics Market Analysis

Factors driving the antibiotics and antimycotics market include the increasing prevalence of infectious diseases caused by bacteria and fungi, and the growing awareness about fungal infections. Surging strategic initiatives such as product launches and approvals, coupled with initiatives by various government and public organizations, are expected to drive the market growth in the future. Moreover, ongoing funding and research & development initiatives are expected to benefit the market progress in the coming years.

Antibiotics and Antimycotics Market Overview

North America dominates the antibiotics and antimycotics market. Asia Pacific is anticipated to register a significant growth rate in the coming years owing to the increasing prevalence of bacterial and fungal infections such as pneumonia, urinary tract infections (UTIs), sexually transmitted diseases, and skin infections in the region. In addition, strategic initiatives such as product launches, product approvals, and developments by the market players are likely to offer lucrative opportunities for the market growth in the coming years.

China is experiencing a surging prevalence of fungal and bacterial infections such as UTI, pneumonia, and respiratory infections, which, in turn, is generating the demand for antibiotics and antimycotics for the treatment and management of such conditions. According to the Epidemiology & Infection Journal , in 2023, ~21.1 million people suffer from community-acquired pneumonia (CAP) every year in China. Furthermore, various pathogens, including bacterial, fungal, and viral, account for 80% of acute respiratory infections among children. A few of the commonly used antibiotics in the country are penicillins, fluoroquinolones, cephalosporins, and nitroimidazoles.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Antibiotics and Antimycotics Market: Strategic Insights

antibiotics-and-antimycotics-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Antibiotics and Antimycotics Market Drivers and Opportunities

Increasing Prevalence of Infectious Diseases Drives Market Growth

Infectious diseases are caused by bacteria, viruses, parasites, fungi, and toxic substances. As per ReAct Group 2022 report, 77 million death cases reported across the world, i.e., 13.6% of total deaths, were linked to bacterial infection, excluding tuberculosis. According to the World Health Organization (WHO), tuberculosis (TB) ranks 13th among the most common causes of death and 2nd among the most frequent infectious diseases, after COVID-19, globally. As per WHO data, 1.3 million people (including 214,000 people affected by HIV) succumbed to TB in 2022. Its estimations also state that 10.6 million people in the world had TB in 2022, including 1.3 million children, 3.5 million women, and 5.8 million men. 30 countries with high TB burdens accounted for 86–90% of new TB cases that year. Eight countries comprised two-thirds of the total, with India leading the way, followed by the Philippines, China, Indonesia, Pakistan, Nigeria, Bangladesh, and South Africa. Rifampin, isoniazid, pyrazinamide, and ethambutol are the prominent antibiotics approved by the US FDA for the treatment of Mycobacterium tuberculosis infections.

Moreover, increasing fungal infections are one of the major concerns among large populations globally. According to the Global Action Fund for Fungal Infections (GAFFI) 2024, every year, more than 80 million people are at high risk of developing fungal disease, and approximately 6.55 million patients develop life-threatening fungal infections annually, of which 3.75 million people die. Azoles and Amphotericin B are a few of the common antimycotics used for the treatment of fungal infections globally. Thus, the rising prevalence of various bacteria and fungi-associated infectious diseases across the world creates a significant need for antibiotics and antimycotics.

Ongoing Funding and Research & Development Initiatives Generate Growth Opportunities

Companies in the antibiotics and antimycotics market are making continuous efforts to develop new products or update the existing ones, and to raise funds for drug development and clinical studies. Initiatives and support from private and government organizations also drive evolution in antibiotics and antimycotics. A few of the recent developments that took place in the market in recent years are mentioned below.

  • In September 2024, F2G, a UK-based biopharmaceutical company, completed a US$ 100-million financing round to conduct the late-stage development and commercialization of olorofim, a novel oral antifungal therapy for invasive aspergillosis and other invasive fungal infections.
  • In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc (Bugworks) signed a collaborative agreement for jointly developing an innovative compound termed BWC0977. This candidate exhibits a broad-spectrum antibiotic activity against multidrug-resistant bacteria responsible for life-threatening infections.
  • In June 2023, BioVersys became the first European company to receive funding for its clinical trials through the AMR Action Fund. This fund operates as the world's second-largest foundation that aims to promote medical research; it is expected to support the launch of 2–4 antimicrobials to combat resistance in bacteria by 2030.
  • In October 2022, CARB-X launched new funding rounds with the goal to focus on critical global health needs in the form of preventatives, diagnostics, and therapeutics that address neonatal sepsis, gonorrhea, and infections caused by antimicrobial-resistant bacteria.

Therefore, the ongoing funding, and research and development initiatives by companies and academic organizations are expected to create ample opportunities for the growth of the antibiotics and antimycotics market in the coming years.

Antibiotics and Antimycotics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the antibiotics and antimycotics market analysis are drug class, indication, route of administration, and distribution channel.

  • Based on drug class, the antibiotics and antimycotics market is categorized into penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. The penicillins segment held the largest share of the market in 2023, and cephalosporins segment is expected to register the highest CAGR in the market during 2023–2031.
  • By indication, the antibiotics and antimycotics market is segmented into skin infections, respiratory infections, urinary tract infections, septicemia, ear infections, gastrointestinal infections, and others. The skin infections segment accounted for the largest share of the market in 2023. The respiratory infections segment is projected to register the highest CAGR in the market during 2023–2031.
  • By route of administration, the antibiotics and antimycotics market is segmented into oral, topical, and others. The oral segment accounted for the largest share of the market in 2023. The others segment is projected to register the highest CAGR in the market during 2023–2031.
  • In terms of distribution channel, the antibiotics and antimycotics market is segmented into hospital pharmacies, retail pharmacies and drug stores, and online pharmacies. The hospital pharmacies segment dominated the market in 2023, and the online pharmacies segment is anticipated to register the highest CAGR during 2023–2031.

Antibiotics and Antimycotics Market Share Analysis by Geography

The geographic scope of the antibiotics and antimycotics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America held a significant share of the market in 2023. The growth of the market in this region is attributed to the rising prevalence of bacterial and fungal infections, and the availability of developed healthcare infrastructure and various antibiotics and antimycotics for treatments. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections, resulting in the evident need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; around 1 million of these are admitted to hospitals, while 50,000 people die due to the condition or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies.

Antibiotics and Antimycotics Market Regional Insights

The regional trends and factors influencing the Antibiotics and Antimycotics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Antibiotics and Antimycotics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

antibiotics-and-antimycotics-market-global-geography
  • Get the Regional Specific Data for Antibiotics and Antimycotics Market

Antibiotics and Antimycotics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 61,207.98 Million
Market Size by 2031 US$ 91,546.07 Million
Global CAGR (2023 - 2031) 5.2%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Drug Class
  • Penicillins
  • Cephalosporins
  • Carbapenems
  • Macrolides
  • Aminoglycosides
  • Quinolones
  • Sulfonamides
  • Tetracyclines
  • Azoles
By Indication
  • Skin Infections
  • Respiratory Infections
  • Urinary Tract Infections
  • Septicemia
  • Ear Infections
  • Gastrointestinal Infections
By Route of Administration
  • Oral
  • Topical
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • Market Players Density: Understanding Its Impact on Business Dynamics

    The Antibiotics and Antimycotics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Antibiotics and Antimycotics Market are:

    1. Pfizer Inc
    2. Novartis AG
    3. Sanofi SA
    4. F. Hoffmann-La Roche Ltd
    5. Merck & Co Inc

    Disclaimer: The companies listed above are not ranked in any particular order.


    antibiotics-and-antimycotics-market-speedometer

    • Get the Antibiotics and Antimycotics Market top key players overview

    Antibiotics and Antimycotics Market News and Recent Developments

    The antibiotics and antimycotics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antibiotics and antimycotics market are listed below:

    • Pfizer Inc. received the European Commission (EC) marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections, hospital-acquired pneumonia, and complicated urinary tract infections. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. EMBLAVEO is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union. (Source: Pfizer Inc, Company Website, April 2024)
    • Orchid Pharma introduced its new Cefepime-Enmetazobactam drug, which has been approved for the treatment of complicated UTIs, hospital-acquired pneumonia, and ventilator-associated pneumonia indications. In a landmark collaboration, Orchid Pharma partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. (Source: Cipla Ltd, Company Website, June 2024)

    Antibiotics and Antimycotics Market Report Coverage and Deliverables

    The "Antibiotics and Antimycotics Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

    • Antibiotics and antimycotics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Antibiotics and antimycotics market trends, as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Antibiotics and antimycotics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the antibiotics and antimycotics market
    • Detailed company profiles
     
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    Which region dominated the antibiotics and antimycotics market in 2023?

    North America dominated the antibiotics and antimycotics market in 2023.

    Which are the leading players operating in the antibiotics and antimycotics market?

    Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key players operating in the antibiotics and antimycotics market.

    What are the factors driving the antibiotics and antimycotics market growth?

    The increasing prevalence of infectious diseases and growing awareness about fungal infections are the common factors fueling the market growth.

    What is the expected CAGR of the antibiotics and antimycotics market?

    The antibiotics and antimycotics market is estimated to register a CAGR of 5.2% during the forecast period.

    What would be the estimated value of the antibiotics and antimycotics market by 2031?

    The antibiotics and antimycotics market value is estimated to reach US$ 91,546.07 million by 2031.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies - Antibiotics and Antimycotics Market

    1. Pfizer Inc 
    2. Novartis AG 
    3. Sanofi SA
    4. F. Hoffmann-La Roche Ltd
    5. Merck & Co Inc 
    6. GSK Plc
    7. Johnson & Johnson
    8. Cipla Ltd
    9. Bayer AG 
    10. AbbVie Inc 
    11. Astellas Pharma Inc

    Buy Now